What would you like to look for?
Site search
7 November 2023

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round. The proceeds will enable Memo Therapeutics AG to complete U.S. Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus infection in kidney transplant recipients.

The VISCHER team advising the lead investor in this transaction included Dr. Matthias Staehelin (Partner, Corporate/M&A), Vincent S. Reardon (Managing Associate, Corporate/M&A), and Adrian Mangold (Senior Associate, Tax).

Authors: Dr. Matthias Staehelin, Vincent S. Reardon, Adrian Hayato Mangold